AIM AIM ImmunoTech Inc
Company Analysis
Latest News
🟢 AIM ImmunoTech is trading 7.29% up in pre-market after European Long COVID patent protection through 2041
AIM ImmunoTech is trading 7.29% up at $0.25 in pre-market after announcing European and United Kingdom patent protection for Ampligen’s Long COVID treatment...
AIM ImmunoTech Secures European Ampligen Patent, Protecting Long COVID Treatment Until 2041
AIM ImmunoTech secured patent protection for its drug Ampligen (rintatolimod) across major European markets and the United Kingdom. This intellectual property...
🔴 AIM ImmunoTech is trading 7.16% down in pre-market
AIM ImmunoTech is trading 7.16% down now at $0.22, with no fresh negative announcement, earnings surprise, or other clear catalyst identified for September...
🟢 AIM ImmunoTech is trading 5.8% up today after announcing broad Ampligen-pembrolizumab patent
AIM ImmunoTech is trading 5.8% up now at $0.24 after announcing a broad U.S. patent covering Ampligen combined with pembrolizumab for cancer treatment. - The...
🟢 AIM ImmunoTech is trading 17.52% up in pre-market after broad U.S. patent covering Ampligen and pembrolizumab
AIM ImmunoTech is trading at $0.27, up 17.52% in pre-market trading on September 1, 2026, after announcing a broad U.S. patent for Ampligen combined with...
🔴 AIM ImmunoTech is trading 10.87% down today after patent-driven interest reversed intraday
AIM ImmunoTech is trading 10.87% down at $0.23 after an intraday reversal from initial buying sparked by its August 31, 2026, announcement of a broad U.S....
🔴 AIM ImmunoTech is trading 6.4% down today after intraday reversal
AIM ImmunoTech is trading at $0.24 (-6.42%) after an intraday reversal following initial buying on its patent announcement. - The company announced a broad...
AIM ImmunoTech's New Cancer Patent Sparks a 34% Rally — But Can a Sub-$10 Million Company Cash In on a $32 Billion Drug Market?
Shares of AIM ImmunoTech surged 34.3% to $0.35 on an otherwise red-tape Monday after the company announced the U.S. Patent and Trademark Office granted it...
🟢 AIM ImmunoTech is trading 34.29% up today after USPTO grants Ampligen-pembrolizumab patent
AIM ImmunoTech is trading 34.29% up now at $0.35 after announcing on August 31, 2026, that the USPTO granted a patent covering Ampligen combined with...
🟢 AIM ImmunoTech is trading 25.66% up today in pre-market
AIM ImmunoTech is trading at $0.32, +25.66%, after rising from the August 28 close of $0.26. • No fresh August 31 company-specific announcement was...
🟢 AIM ImmunoTech is trading 5.7% up today with broader biotechnology momentum
AIM ImmunoTech is trading 5.7% up at $0.27, with broader biotechnology momentum and improving risk appetite appearing to support the move. - The stock...
🔴 AIM ImmunoTech is trading 5.1% down in pre-market — reason for decline remains unconfirmed
AIM ImmunoTech is trading 5.1% down now at $0.24 in pre-market, with the reason for the decline unconfirmed. - No new company-specific announcement was...
🟢 AIM ImmunoTech is trading 6.21% up today amid biotech momentum after positive Moderna cancer-vaccine news
AIM ImmunoTech is trading 6.21% up at $0.25, apparently amid residual biotech momentum following positive Moderna cancer-vaccine news. - No newly identified...
🟢 AIM ImmunoTech is trading 7.83% up in after-hours trading on biotech-sector strength after positive Moderna cancer-vaccine results
AIM ImmunoTech is trading 7.83% up at $0.26 in after-hours trading after the broader biotech sector rallied on positive Moderna personalized cancer-vaccine...
🟢 AIM ImmunoTech rises 5.2% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 AIM ImmunoTech is trading 11.69% up today with no clear company-specific catalyst
AIM ImmunoTech is trading 11.69% up at $0.25, with no clear company-specific catalyst identified for August 17, 2026. - Recent second-quarter results, the...
🟢 AIM ImmunoTech is trading 6.3% up today — no clear company-specific catalyst identified
AIM ImmunoTech is trading at $0.23 (+6.28%) with no clear company-specific catalyst identified for the August 17, 2026 move. - Recent second-quarter results...
🟢 AIM ImmunoTech is trading 11.6% up in pre-market with no clear company-specific catalyst identified
AIM ImmunoTech is trading 11.6% up in pre-market at $0.25 after closing at $0.22 on August 14, 2026, with no clear company-specific catalyst identified. -...
🟢 AIM ImmunoTech is trading 7.32% up in pre-market with no clear catalyst identified
AIM ImmunoTech is trading 7.32% up at $0.24, with no clear company-specific catalyst identified for the August 17 pre-market move. - The company closed August...
🟢 AIM ImmunoTech is trading 5.7% up in after-hours trading with no clear company-specific catalyst identified
AIM ImmunoTech is trading 5.69% up now at $0.23 after closing August 14, 2026 at $0.22, with no clear company-specific catalyst identified for the after-hours...